GLP-1 weight-loss pills appear to be just as effective as injections, with clinical trials showing similar average weight ...

There's now a prescription GLP-1 pill for weight loss on the market. Here are six key things to know about it.

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

GLP-1 agonists and dual agonists can cause hypoglycemia, nausea, and more. Here's how to lessen the side effects.

Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access ...

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ...

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

The once-daily Wegovy pill became the first oral GLP-1 approved for weight loss in the U.S., offering an alternative to ...

The FDA has approved a pill form of the popular injectable obesity drug Wegovy. People on the highest dose dropped about 14 percent of their starting weight after 64 weeks, with a high number of ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase II ...